FDA committee favors restricting prostate cancer regimen to BRCA -positive subgroup
An FDA advisory committee recommended that a proposed indication for olaparib with abiraterone acetate as first-line treatment for metastatic castration-resistant prostate cancer be limited to patients whose tumors have BRCA mutations.The Oncologic Drugs Advisory Committee voted 11 to 1 in favor of the restriction. One committee member abstained.